Chapter 9

Bevacizumab Toxicity in Glioblastoma

Dawit Aregawi and David Schiff

Abstract

<p>Bevacizumab recently received approval from the United States Food and Drug Administration for use in recurrent glioblastoma. Although, most patients tolerate bevacizumab with tolerable side effects, occasional patients sustain life-threatening complications and many others require medical management in order to continue on the drug. This chapter reviews the spectrum of bevacizumab complications in patients with malignant glioma, including mechanism when known as well as management.</p>

Total Pages: 46-50 (5)

Purchase Chapter  Book Details